BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals

Published on 2025-06-12 at 07:00 - Modified on 2025-06-12 at 09:57

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Merck & Co., Inc.

US FDA approves pre-filled version of GSK's shingles vaccine	07:05am	RE
Trump Reportedly Says New Pharmaceutical Tariffs Likely by July-End	07-16	MT
Sino Biopharmaceutical to acquire LaNova Medicines for up to $951 million	07-15	RE
Merck & Co., Inc. to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill	07-14	CI
Merck & Co advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally	07-14	RE
Merck to Start Phase 3 Trials of MK-8527 for HIV Prevention	07-14	MT
Health Rounds: Experimental Bayer drug eases menopause-like symptoms from breast cancer therapy	07-11	RE
Global markets live: Tesla, Nvidia, Google, BP, Nissan…	07-11
MERCK : Jefferies raises TP after Verona acquisition	07-11
FDA May Fast Track Drug Reviews for Lower US Prices, Bloomberg Reports	07-11	MT
Wall Street Waits to Hear the Numbers	07-11
Jefferies Adjusts Merck & Co.'s Price Target to $141 From $138, Keeps Buy Rating	07-11	MT
Merck: Jefferies raises TP after Verona acquisition	07-11
Merck: FDA approval for Bravecto Quantum	07-11
Merck: seeks FDA approval for new HIV treatment	07-11
Merck Animal Health's Flea-and-Tick Treatment Approved in U.S.	07-10	DJ
Merck Animal Health Gets FDA Approval for Bravecto Quantum	07-10	MT
Fda approves Bravecto Quantum, a long-acting injectable for dogs 6 months and older	07-10	RE
Morgan Stanley Adjusts Price Target on Merck to $98 From $99, Maintains Equalweight Rating	07-10	MT
Global markets live: Nvidia, Tesla, Blackstone, BMW, Samsung…	07-10
AI Mania Masks Trade War Risks	07-10
U.S. FDA Accepts New Drug Application for Merck's Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection	07-10	CI
Merck Says FDA Accepts for Review New Drug Application for Doravirine/Islatravir to Treat HIV-1 Infection in Adults	07-10	MT
Merck : FDA to Review Doravirine/Islatravir Regimen in HIV-1 Infection	07-10	DJ
U.S. FDA accepts new drug application for Merck's doravirine/islatravir	07-10	RE